author-photo

J Leveque

Eli Lilly and Company

12

Papers

103

Citations

Citation Trend

Filter By

Papers (7) Sort By

Journal Conference Others

Abstract A016: PEGylated IL-10 (pegilodecakin) induces systemic immune activation, CD8+ T-cell invigoration and polyclonal T-cell expansion in cancer patients

2019 Cancer immunology research
Show All
- Source
- Cite
- Save
Citations (0)
MA04.02 Responses and Durability in NSCLC Treated With Pegilodecakin and Anti-PD-1

2018 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (0)
1146PDurability of clinical benefit in metastatic epithelial ovarian cancer patients treated with pegilodecakin monotherapy or in combination with platinum plus taxane-based chemotherapy

2018 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
1144PResponses and durability of clinical benefit in non-small cell lung cancer treated with pegilodecakin in combination with anti-PD-1 inhibitors

2018 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (1)
PEGylated IL-10 (Pegilodecakin) Induces Systemic Immune Activation, CD8 + T Cell Invigoration and Polyclonal T Cell Expansion in Cancer Patients

2018 Cancer Cell
Show All
- Source
- Cite
- Save
Citations (88)
1130OResponses and durability of clinical benefit in renal cell carcinoma treated with pegilodecakin in combination with anti-PD-1 inhibitors

2018 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
1145PResponses and durability of clinical benefit in triple negative breast cancer patients treated with pegilodecakin monotherapy or in combination with platinum plus taxane-based chemotherapy

2018 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)